S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
Log in
NASDAQ:ALNA

Allena Pharmaceuticals Stock Forecast, Price & News

$1.68
+0.05 (+3.07 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.58
Now: $1.68
$1.69
50-Day Range
$1.25
MA: $1.36
$1.64
52-Week Range
$0.53
Now: $1.68
$3.39
Volume1.21 million shs
Average Volume1.52 million shs
Market Capitalization$64.33 million
P/E RatioN/A
Dividend YieldN/A
Beta2.39
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and moderate to severe chronic kidney diseases. Allena Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Newton, Massachusetts.
Allena Pharmaceuticals logo

MarketRank

Overall MarketRank

1.31 out of 5 stars

Medical Sector

668th out of 1,923 stocks

Biological Products, Except Diagnostic Industry

90th out of 177 stocks

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALNA
CUSIPN/A
Phone617-467-4577
Employees32

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.73 per share

Profitability

Net Income$-47,340,000.00

Miscellaneous

Market Cap$64.33 million
Next Earnings Date3/15/2021 (Estimated)
OptionableNot Optionable
$1.68
+0.05 (+3.07 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALNA News and Ratings via Email

Sign-up to receive the latest news and ratings for ALNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Allena Pharmaceuticals (NASDAQ:ALNA) Frequently Asked Questions

How has Allena Pharmaceuticals' stock price been impacted by Coronavirus?

Allena Pharmaceuticals' stock was trading at $1.26 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ALNA stock has increased by 33.3% and is now trading at $1.68.
View which stocks have been most impacted by COVID-19
.

Is Allena Pharmaceuticals a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Allena Pharmaceuticals stock.
View analyst ratings for Allena Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Allena Pharmaceuticals?

Wall Street analysts have given Allena Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Allena Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Louis Brenner, M.D.'s approval rating as Allena Pharmaceuticals' CEO?

1 employees have rated Allena Pharmaceuticals CEO Louis Brenner, M.D. on Glassdoor.com. Louis Brenner, M.D. has an approval rating of 100% among Allena Pharmaceuticals' employees. This puts Louis Brenner, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When is Allena Pharmaceuticals' next earnings date?

Allena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for Allena Pharmaceuticals
.

How were Allena Pharmaceuticals' earnings last quarter?

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) announced its quarterly earnings results on Saturday, November, 14th. The company reported ($0.22) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.01.
View Allena Pharmaceuticals' earnings history
.

What price target have analysts set for ALNA?

6 brokers have issued 1-year target prices for Allena Pharmaceuticals' stock. Their forecasts range from $4.00 to $18.00. On average, they expect Allena Pharmaceuticals' share price to reach $9.33 in the next year. This suggests a possible upside of 455.6% from the stock's current price.
View analysts' price targets for Allena Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Who are some of Allena Pharmaceuticals' key competitors?

What other stocks do shareholders of Allena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), VYNE Therapeutics (VYNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Acasti Pharma (ACST) and Miragen Therapeutics (MGEN).

Who are Allena Pharmaceuticals' key executives?

Allena Pharmaceuticals' management team includes the following people:
  • Dr. Alexey L. Margolin, Co-Founder & Chairman (Age 67, Pay $734.38k)
  • Dr. Louis Brenner, Pres, CEO & Director (Age 50, Pay $507.28k)
  • Mr. Edward J. Wholihan, Chief Financial Officer (Age 60, Pay $387.03k)
  • Mr. Robert Gallotto, Co-Founder & Strategic Adviser (Age 55)
  • Mr. Geoffrey A. Swire, Sr. VP of Corp. Devel., Acting COO & Interim Principal Operating Officer (Age 48)
  • Mr. Hugh Wight, Sr. VP of Technical Operations
  • Dr. David J. Clark, Chief Medical Officer (Age 55)

When did Allena Pharmaceuticals IPO?

(ALNA) raised $80 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,300,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Allena Pharmaceuticals' stock symbol?

Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA."

How do I buy shares of Allena Pharmaceuticals?

Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Allena Pharmaceuticals' stock price today?

One share of ALNA stock can currently be purchased for approximately $1.68.

How big of a company is Allena Pharmaceuticals?

Allena Pharmaceuticals has a market capitalization of $64.33 million. The company earns $-47,340,000.00 in net income (profit) each year or ($2.10) on an earnings per share basis. Allena Pharmaceuticals employs 32 workers across the globe.

What is Allena Pharmaceuticals' official website?

The official website for Allena Pharmaceuticals is www.allenapharma.com.

How can I contact Allena Pharmaceuticals?

Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at 617-467-4577.

This page was last updated on 1/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.